Philipp Welschof

764 total citations
9 papers, 657 citations indexed

About

Philipp Welschof is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Clinical Biochemistry. According to data from OpenAlex, Philipp Welschof has authored 9 papers receiving a total of 657 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Endocrinology, Diabetes and Metabolism, 3 papers in Molecular Biology and 3 papers in Clinical Biochemistry. Recurrent topics in Philipp Welschof's work include Diabetes Treatment and Management (5 papers), Nitric Oxide and Endothelin Effects (3 papers) and Receptor Mechanisms and Signaling (2 papers). Philipp Welschof is often cited by papers focused on Diabetes Treatment and Management (5 papers), Nitric Oxide and Endothelin Effects (3 papers) and Receptor Mechanisms and Signaling (2 papers). Philipp Welschof collaborates with scholars based in Germany, France and United Kingdom. Philipp Welschof's co-authors include Thomas Münzel, Andreas Daiber, Eberhard Schulz, Matthias Oelze, Swenja Kröller‐Schön, Sebastian Steven, Eric Mayoux, Serge P. Bottari, Paul Stamm and Michael Hausding and has published in prestigious journals such as PLoS ONE, Free Radical Biology and Medicine and Arteriosclerosis Thrombosis and Vascular Biology.

In The Last Decade

Philipp Welschof

9 papers receiving 642 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Philipp Welschof Germany	7	429	228	226	127	112	9	657
Elena Zinßius Germany	6	279 0.7×	135 0.6×	212 0.9×	108 0.9×	138 1.2×	7	596
Alina Hanf Germany	6	203 0.5×	136 0.6×	185 0.8×	145 1.1×	114 1.0×	6	555
Ryo Kodera Japan	10	372 0.9×	188 0.8×	170 0.8×	65 0.5×	59 0.5×	16	648
Nobuo Kajitani Japan	9	340 0.8×	161 0.7×	168 0.7×	68 0.5×	63 0.6×	10	640
Markus Alter Germany	15	458 1.1×	157 0.7×	217 1.0×	194 1.5×	99 0.9×	23	862
Maria Oliveira‐Souza Brazil	17	279 0.7×	178 0.8×	321 1.4×	104 0.8×	55 0.5×	34	696
Michihiro Matsuki Japan	12	317 0.7×	251 1.1×	180 0.8×	81 0.6×	123 1.1×	39	667
Chikage Sato Japan	8	290 0.7×	146 0.6×	169 0.7×	50 0.4×	62 0.6×	9	551
Motofumi Sasaki Japan	13	334 0.8×	177 0.8×	202 0.9×	139 1.1×	72 0.6×	16	781
Mihoko Hosoba Japan	10	343 0.8×	157 0.7×	189 0.8×	82 0.6×	116 1.0×	14	750

Countries citing papers authored by Philipp Welschof

Since Specialization

Citations

This map shows the geographic impact of Philipp Welschof's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philipp Welschof with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philipp Welschof more than expected).

Fields of papers citing papers by Philipp Welschof

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philipp Welschof. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philipp Welschof. The network helps show where Philipp Welschof may publish in the future.

Co-authorship network of co-authors of Philipp Welschof

This figure shows the co-authorship network connecting the top 25 collaborators of Philipp Welschof. A scholar is included among the top collaborators of Philipp Welschof based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philipp Welschof. Philipp Welschof is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Oelze, Matthias, Philipp Welschof, Maike Knorr, et al.. (2017). Basic in vitro Characterization of the Vasodilatory Potential of 2-Aminoethyl Nitrate Fixed-Dose Combinations with Cilostazol, Metoprolol and Valsartan. Pharmacology. 101(1-2). 54–63. 1 indexed citations

Steven, Sebastian, Matthias Oelze, Alina Hanf, et al.. (2017). The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats. Redox Biology. 13. 370–385. 243 indexed citations

Hanf, Alina, Sebastian Steven, Matthias Oelze, et al.. (2017). The SGLT2 Inhibitor Empagliflozin Improves the Primary Diabetic Complications in ZDF Rats. Free Radical Biology and Medicine. 112. 112–113. 6 indexed citations

Mikhed, Yuliya, Jörg Fahrer, Matthias Oelze, et al.. (2016). Nitroglycerin induces DNA damage and vascular cell death in the setting of nitrate tolerance. Basic Research in Cardiology. 111(4). 11 indexed citations

Steven, Sebastian, Michael Hausding, Swenja Kröller‐Schön, et al.. (2015). Gliptin and GLP‐1 analog treatment improves survival and vascular inflammation/dysfunction in animals with lipopolysaccharide‐induced endotoxemia. Basic Research in Cardiology. 110(2). 6–6. 99 indexed citations

Jabs, Alexander, Matthias Oelze, Yuliya Mikhed, et al.. (2015). Effect of soluble guanylyl cyclase activator and stimulator therapy on nitroglycerin-induced nitrate tolerance in rats. Vascular Pharmacology. 71. 181–191. 28 indexed citations

Stamm, Paul, Alexander Jabs, Matthias Oelze, et al.. (2015). Effect of soluble guanylyl cyclase activator and stimulator therapy on nitroglycerin-induced nitrate tolerance in rats. BMC Pharmacology and Toxicology. 16(S1). 7 indexed citations

Oelze, Matthias, Swenja Kröller‐Schön, Philipp Welschof, et al.. (2014). The Sodium-Glucose Co-Transporter 2 Inhibitor Empagliflozin Improves Diabetes-Induced Vascular Dysfunction in the Streptozotocin Diabetes Rat Model by Interfering with Oxidative Stress and Glucotoxicity. PLoS ONE. 9(11). e112394–e112394. 260 indexed citations

Welschof, Philipp, Matthias Oelze, Swenja Kröller‐Schön, et al.. (2014). Abstract 412: The Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin Improves Diabetic Complications in the Streptozotocin Type 1 Diabetes Mellitus Model by Interfering With Glucotoxicity and Rescue of Beta-Cell Function. Arteriosclerosis Thrombosis and Vascular Biology. 34(suppl_1). 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact